Sionna Therapeutics Inc - SION EV/EBITDA Multiple

Symbol and logo of brand sionnatx.com (SION)

A virtual R&D model delegating synthesis to CRO laboratories is driving growth, as confirmed by the EV/EBITDA multiple chart for Sionna Therapeutics Inc (SION), where 0.00 is recorded as the baseline value. The business foundation relies on the sale of agents for CFTR protein restoration in cystic fibrosis. The advantage of Sionna Therapeutics Inc (SION) lies in the molecular stabilization of defective proteins, creating unique opportunities for gene therapy.

SION (Sionna Corp) Business Value to Operating Income Before Depreciation history from 11/23/2025 to 11/15/2026

Comprehensive metric breakdowns and analytics for Sionna Therapeutics (SION)

- market price and analyst price targets:
Initial company analysis:SION (Sionna Therapeutics Inc)
Product sample of sionnatx.com

The EV/EBITDA ratio determines the enterprise value including debt relative to operating profit, allowing an investor to assess the asset payback period and the level of debt load. Analyzing the EV/EBITDA multiple of Sionna Therapeutics Inc (SION) reveals how a strategy of full outsourcing for clinical trials and production minimizes capital expenditures, stabilizing the issuer's fundamental valuation.

Key competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempus AI TEM|qiagen.com (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Repligen (RGEN)|RNA (Avidity) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics AG - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GeneDx Holdings|Enterprise Value to Operating Income Before Depreciation RARE (Ultragenyx)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics (BEAM)|Enterprise Value to Operating Income Before Depreciation Ratio SRPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience Corp TWST|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics, Inc. (TXG)|Intellia Therapeutics - EV/EBITDA Multiple|STOK - EV/EBITDA Multiple|BLFS (biolifesolutions.com) - Enterprise Value to EBITDA Ratio|WVE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio MAZE|Enterprise Value to Operating Income Before Depreciation PRME (Prime Medicine Corp)|EV/EBITDA Multiple TSHA|EV/EBITDA Multiple uniqure.com (QURE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MeiraGTx PLC MGTX|Business Value to Operating Income Before Depreciation RGNX|solidbio.com - EV/EBITDA Multiple|OCGN (Ocugen Pharma) - Enterprise Value to Operating Income Before Depreciation|PACB: EV/EBITDA Multiple|Benitec Biopharma (BNTC) - EV/EBITDA Multiple|DSGN (Design Therapeutics Inc) - EV/EBITDA Multiple|Rocket Pharmaceuticals, Inc. (RCKT) - Total Company Value to Operating Income Before Depreciation Ratio|FDMT - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LXEO (Lexeo)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization korrobio.com KRRO|Total Company Value to Operating Income Before Depreciation Ratio Editas Medicine, Inc. (EDIT)|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ProQR PRQR|CDXS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Sangamo BioSciences SGMO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Bio|MGX (Metagenomi, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple DTIL|Generation Bio - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio Inc.)|Business Value to Operating Income Before Depreciation XCUR|Imunon Inc - EV/EBITDA Multiple|PHIO (phiopharma.com) - Enterprise Value to Operating Income Before Depreciation|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Corp|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple ImmunoPrecise Antibodies Ltd. (IPA)|EV/EBITDA Multiple OMGA (omegatherapeutics.com)|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals, Inc)|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology, Inc